Short Bowel Syndrome Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class ( GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region, By Competition

Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Short Bowel Syndrome Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class ( GLP-2, Glutamine, and Growth Hormone), By Distribution Channel (Hospital Pharmacies, Online Sales, and Retail Pharmacies), By Region, By Competition

Forecast Period2024-2028
Market Size (2022)USD 805.11 million
CAGR (2023-2028)6.24%
Fastest Growing SegmentOnline Sales
Largest MarketNorth America

MIR Consumer Healthcare

Market Overview

Global Short Bowel Syndrome Market

Short Bowel Syndrome is primarily a result of surgical removal or damage to a significant portion of the small intestine. This can occur due to various factors, such as congenital defects, trauma, or diseases like Crohn's disease. The condition manifests through symptoms like diarrhea, malabsorption of nutrients, electrolyte imbalances, and weight loss. The global Short Bowel Syndrome market has experienced substantial growth in recent years. Several factors contribute to this, including an increased awareness of the condition, advances in medical technology, and a growing patient population. The prevalence of Short Bowel Syndrome has been on the rise, driving the demand for effective treatment options. This increase can be attributed to better diagnostic techniques and an aging population. Traditional treatment approaches for SBS focused on dietary management and parenteral nutrition. However, the market has seen a shift towards innovative therapies such as intestinal rehabilitation, microbiome-based treatments, and tissue engineering. Several pharmaceutical companies and research institutions are actively involved in the development of therapies and drugs for SBS. These players compete in a dynamic market, fostering innovation and new discoveries.

Kye Market Drivers

Increasing Incidence of Short Bowel Syndrome is Driving the Global Short Bowel Syndrome Market

The rise in Short Bowel Syndrome cases has led to an increased demand for treatments and therapies, which in turn is driving the growth of the global Short Bowel Syndrome market.

The increasing incidence of Short Bowel Syndrome is a pressing healthcare concern that is driving the growth of the global Short Bowel Syndrome market. Factors such as medical advancements, improved survival rates for preterm infants, and the rising prevalence of inflammatory bowel diseases are contributing to this trend. The pharmaceutical, nutritional, and surgical sectors are all responding with innovations and treatments to improve the lives of those affected by SBS. As research and development continue to advance, there is hope for better management and improved outcomes for individuals living with this challenging condition.

Rising Investment in Research and Development is Driving the Global Short Bowel Syndrome Market

The global Short Bowel Syndrome market is experiencing a significant boost due to increased investment in R&D activities. This surge in funding is primarily driven by a growing understanding of the disease, advancements in medical technology, and a commitment to improving the quality of life for SBS patients.

Recent R&D initiatives have led to the development of innovative therapies that address the underlying causes of SBS. One such breakthrough is the development of tissue-engineered intestines, which have the potential to replace damaged or missing parts of the small intestine. These therapies hold promise for SBS patients who previously had limited treatment options. R&D efforts have also resulted in the creation of specialized nutritional formulations tailored to the unique needs of SBS patients. These formulations help patients meet their nutritional requirements and improve their overall health and well-being. This has led to an increased demand for such products in the market. Pharmaceutical companies are actively investing in the development of drugs that can enhance nutrient absorption in SBS patients. These drugs aim to reduce dependence on parenteral nutrition (intravenous feeding) and improve patients' ability to absorb nutrients orally, ultimately improving their quality of life. The surge in R&D investment has led to a rise in clinical trials focused on Short Bowel Syndrome. These trials not only help in evaluating the safety and efficacy of new treatments but also provide valuable data that can guide further research and development efforts.

The rising investment in research and development is transforming the landscape of the global Short Bowel Syndrome market. With innovative therapies, advanced nutritional support, and promising drug candidates in the pipeline, SBS patients can look forward to improved treatment options and a better quality of life. As R&D efforts continue to flourish, it is likely that the market will expand further, offering hope to those affected by this rare and challenging condition. Ultimately, the synergy between research, investment, and patient advocacy is driving the global Short Bowel Syndrome market toward a brighter future.


MIR Segment1

Key Market Challenges

Limited Patient Pool

One of the primary challenges faced by the Global Short Bowel Syndrome Market is the limited patient pool. SBS is considered a rare disease, with only a relatively small number of diagnosed cases worldwide. This limited patient base makes it economically challenging for pharmaceutical companies to invest in the development of specialized treatments and therapies for SBS. Consequently, potential breakthroughs may not receive the funding and attention they deserve.

High Treatment Costs

The treatment of SBS is notoriously expensive. Patients often require lifelong medical care, including parenteral nutrition and specialized medications. Additionally, the cost of surgery and post-operative care can be substantial. As a result, patients, healthcare systems, and insurance providers face the daunting challenge of covering these high treatment costs, potentially leading to financial strain and limited access to care.

Nutritional Challenges

Patients with SBS often struggle to maintain proper nutrition and fluid balance due to the reduced length of their small intestine. Nutritional deficiencies and dehydration are common issues, necessitating ongoing dietary management and the use of specialized nutritional supplements. Ensuring that patients receive adequate nutrition while minimizing complications is a complex and ongoing challenge.


MIR Regional

Development of Effective Therapies

The development of effective therapies for SBS is an ongoing struggle. While there have been some advances in the form of medications and medical devices, there is no one-size-fits-all treatment for this condition. Researchers face the challenge of tailoring therapies to individual patients, considering factors such as the length of the remaining intestine and the underlying cause of SBS. This level of customization makes treatment development complex and resource-intensive.

Lack of Awareness and Diagnosis

SBS is often misdiagnosed or diagnosed at a late stage, primarily because of its rarity and the absence of specific symptoms. This delay in diagnosis can lead to complications and worsen the patient's condition. Raising awareness among healthcare professionals and the general public about the symptoms and risk factors associated with SBS is crucial for early intervention and improved outcomes.

Regulatory and Market Access Barriers

Navigating the regulatory landscape for SBS treatments can be challenging. The approval process for new therapies can be lengthy and complex, and ensuring market access for these treatments can be a significant hurdle. Companies must demonstrate the safety and efficacy of their products while addressing the unique needs of the SBS patient population.

Quality of Life and Long-Term Outcomes

Beyond medical treatment, patients with SBS face ongoing challenges related to their quality of life and long-term outcomes. Managing SBS often involves adapting to dietary restrictions, dealing with complications such as intestinal failure-associated liver disease, and coping with the emotional and psychological impact of the condition. Addressing these aspects of SBS care is essential for comprehensive patient management.

Key Market Trends

Technological Advancements

Short Bowel Syndrome (SBS) is a rare, yet debilitating condition that affects individuals who have lost a significant portion of their small intestine, typically due to surgery or disease. This condition can lead to severe malabsorption of nutrients, causing patients to suffer from malnutrition and other related complications. Fortunately, recent advancements in medical technology have been driving significant growth in the global Short Bowel Syndrome market, offering hope to those afflicted with this condition

The global Short Bowel Syndrome market is undergoing a transformation driven by remarkable technological advancements. These innovations are improving the lives of SBS patients by offering more effective treatments, better nutritional support, and enhanced monitoring options. As pharmaceutical companies continue to invest in research and development, and medical technology continues to evolve, there is optimism that the future holds even more promising solutions for individuals suffering from Short Bowel Syndrome. This progress not only provides hope for those afflicted with the condition but also underscores the broader potential of technology to revolutionize healthcare across various medical domains.

Drug Class Insights

The Glutamine segment is projected to experience rapid growth during the forecast period. Glutamine is an amino acid naturally present in the body, with a vital role in various metabolic processes. In recent years, it has gained prominence in the treatment of Short Bowel Syndrome, owing to its ability to support intestinal health and improve nutrient absorption. Glutamine is found at in both oral and intravenous forms, making it a versatile choice for SBS patients. Clinical studies have shown that Glutamine supplementation can help maintain the integrity of the intestinal mucosa, reduce diarrhea, and improve nutrient absorption. This translates to better nutritional outcomes for SBS patients. Glutamine is generally well-tolerated and has a favorable safety profile. This makes it a preferred choice for long-term use, reducing the risk of adverse effects commonly associated with other treatments like PN. The availability of both oral and intravenous forms of Glutamine allows healthcare providers to tailor treatment to individual patient needs. This flexibility is crucial for optimizing therapy.

Distribution Channel Insights

Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global Short Bowel Syndrome market in 2022, holding the largest market share in terms of value. North America has long been at the forefront of medical research and development, and this holds true for SBS as well. The region boasts a robust infrastructure of research institutions, pharmaceutical companies, and healthcare facilities. Prominent universities and medical centers in the United States and Canada have actively engaged in clinical trials and research initiatives aimed at improving SBS management. The United States Food and Drug Administration (FDA) and Health Canada are renowned for their stringent yet efficient regulatory processes. These agencies play a pivotal role in ensuring the safety and efficacy of new SBS treatments. Companies operating in North America benefit from a transparent and well-defined regulatory pathway, which encourages innovation and investment in the SBS market. North America is home to some of the world's largest pharmaceutical companies, many of which have invested heavily in SBS research and development. These industry giants have the financial capacity and expertise to conduct extensive clinical trials and bring innovative treatments to market. Their involvement in the SBS market has driven significant advancements in treatment options.

Recent Developments

  • InSeptember 2022, Zealand Pharma A/S revealed encouraging outcomes from a phase 3study of Glepaglutide aimed at addressing short bowel syndrome. Glepaglutide isa promising long-acting GLP-2 analog that could potentially outperformTeduglutide due to its unique benefits such as weekly administration and anextended duration of action.
  • InJune 2021, Takeda Pharmaceutical Company Limited introduced Gattex/Revestive, asubcutaneous injection designed for the treatment of short bowel syndrome, inJapan and obtained the green light from the Ministry of Health, Labor, andWelfare.

Key Market Players

  • 9 Meters Biopharma, Inc.
  • WellspectHealthcare
  • EmmausLife Sciences, Inc.
  • MerckKGaA
  • NestleS.A.
  • NovartisInternational AG
  • OPKOHealth, Inc.
  • OxtheraAB
  • PfizerInc.
  • PhaseBioPharmaceuticals Inc.
  • Sancilioand Company, Inc.
  • SwedishOrphan Biovitrum AB
  • TakedaPharmaceutical Company Limited
  • TevaPharmaceutical Industries Ltd.

By Drug Class

By Distribution Channel

By Region

  • GLP-2
  • Glutamine
  • Growth Hormone
  • Hospital Pharmacies
  • Online Sales
  • Retail Pharmacies
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.